| scholarly article | Q13442814 |
| P50 | author | Stephen L Chan | Q60487174 |
| Winnie Yeo | Q56798869 | ||
| P2093 | author name string | Stephen L Chan | |
| Winnie Yeo | |||
| P2860 | cites work | Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics | Q58814455 |
| Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling | Q24316697 | ||
| Modes of resistance to anti-angiogenic therapy | Q24608005 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis | Q24805089 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Phase II Trial of Sorafenib Combined With Concurrent Transarterial Chemoembolization With Drug-Eluting Beads for Hepatocellular Carcinoma | Q28247867 | ||
| Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 | ||
| The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat | Q28360983 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma | Q29617957 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. | Q33382749 | ||
| Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study | Q33384665 | ||
| Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study | Q33385313 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study | Q33392573 | ||
| Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | Q33747394 | ||
| Targeting insulin-like growth factor axis in hepatocellular carcinoma | Q33951057 | ||
| Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer | Q34560933 | ||
| Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma | Q34566598 | ||
| Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma | Q34593345 | ||
| A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas | Q34611637 | ||
| Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype | Q34619635 | ||
| Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast gro | Q34752683 | ||
| Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma | Q35023451 | ||
| O2 regulates stem cells through Wnt/β-catenin signalling. | Q35129302 | ||
| c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma | Q35235798 | ||
| Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. | Q35584967 | ||
| Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma | Q35587117 | ||
| HCC and angiogenesis: possible targets and future directions | Q35698574 | ||
| Angiogenesis and hepatocellular carcinoma | Q35935624 | ||
| Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level | Q36065624 | ||
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma | Q36160273 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α | Q36926447 | ||
| Pivotal role of mTOR signaling in hepatocellular carcinoma | Q37183244 | ||
| Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair | Q37357884 | ||
| The role of signaling pathways in the development and treatment of hepatocellular carcinoma | Q37773788 | ||
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 | ||
| Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma | Q37847011 | ||
| Cancer epigenetics reaches mainstream oncology | Q37851012 | ||
| Molecular classification of hepatocellular carcinoma anno 2011. | Q37879751 | ||
| Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma | Q39336768 | ||
| Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. | Q39452813 | ||
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Q39585554 | ||
| Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells | Q39660893 | ||
| The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines | Q39890460 | ||
| Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma | Q39907568 | ||
| What brings pericytes to tumor vessels? | Q39961338 | ||
| Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas | Q40165067 | ||
| Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma | Q40446595 | ||
| Staging systems in hepatocellular carcinoma | Q42576509 | ||
| A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma | Q43846809 | ||
| mTOR and P70 S6 kinase expression in primary liver neoplasms | Q45205087 | ||
| Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis | Q45370630 | ||
| The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. | Q45915696 | ||
| The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma | Q46081339 | ||
| A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer | Q46147119 | ||
| In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models | Q46173286 | ||
| Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness | Q46821572 | ||
| Expression of vascular endothelial growth factor in human hepatocellular carcinoma | Q47872949 | ||
| Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. | Q51731281 | ||
| A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. | Q54681050 | ||
| Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 | ||
| Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization | Q58257793 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatocellular carcinoma | Q1148337 |
| P304 | page(s) | 862-872 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | Journal of Gastroenterology and Hepatology | Q15764401 |
| P1476 | title | Targeted therapy of hepatocellular carcinoma: present and future | |
| P478 | volume | 27 |
| Q89057719 | A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma |
| Q88125526 | A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma |
| Q38652256 | A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. |
| Q38020234 | Anti-angiogenic drug discovery: lessons from the past and thoughts for the future |
| Q55544709 | Anti-proliferative Effect of 15,16-Dihydrotanshinone I Through Cell Cycle Arrest and the Regulation of AMP-activated Protein Kinase/Akt/mTOR and Mitogen-activated Protein Kinase Signaling Pathway in Human Hepatocellular Carcinoma Cells. |
| Q36097965 | Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract |
| Q38993878 | Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma. |
| Q38126730 | Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma |
| Q37635310 | Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy |
| Q26799048 | Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma |
| Q38201707 | Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights. |
| Q34141891 | Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells |
| Q34458068 | Drug development for hepatocellular carcinoma: knowing the past helps to understand the future |
| Q37581334 | Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives |
| Q35739362 | Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma |
| Q42343440 | Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib |
| Q26784412 | Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma |
| Q36153539 | Hepatocellular Carcinoma Patients With Performance Status 1 Deserve New Classification and Treatment Algorithm in the BCLC System |
| Q36083511 | Huaier polysaccharide induces apoptosis in hepatocellular carcinoma cells through p38 MAPK. |
| Q36414502 | Interaction of the Hepatitis B Spliced Protein with Cathepsin B Promotes Hepatoma Cell Migration and Invasion |
| Q33914111 | KCTD11 inhibits growth and metastasis of hepatocellular carcinoma through activating Hippo signaling |
| Q91860487 | Lycopene enriched tomato extract suppresses chemically induced skin tumorigenesis in mice |
| Q33807180 | Magnetic alginate microspheres detected by MRI fabricated using microfluidic technique and release behavior of encapsulated dual drugs |
| Q28072595 | Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016 |
| Q37995523 | Management of hepatocellular carcinoma: beyond sorafenib. |
| Q38212573 | Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future |
| Q38440838 | Novel therapeutic targets and predictive markers for hepatocellular carcinoma |
| Q39172796 | Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. |
| Q34995167 | Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways |
| Q42330057 | Proteomics approaches for early detection and targeted therapy of hepatocellular carcinoma |
| Q35229808 | Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma |
| Q37725521 | Recombinant adeno-associated virus expressing a p53-derived apoptotic peptide (37AA) inhibits HCC cells growth in vitro and in vivo |
| Q38207013 | Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma |
| Q52957364 | Suppression of the nuclear transporter-KPNβ1 expression inhibits tumor proliferation in hepatocellular carcinoma |
| Q26830913 | Systemic treatment for inoperable pancreatic adenocarcinoma: review and update |
| Q37705967 | TGF-β Mediated Crosstalk Between Malignant Hepatocyte and Tumor Microenvironment in Hepatocellular Carcinoma |
| Q38114062 | Targeted Therapies in the Treatment of Advanced Hepatocellular Carcinoma |
| Q52614692 | Targeting DTL induces cell cycle arrest and senescence and suppresses cell growth and colony formation through TPX2 inhibition in human hepatocellular carcinoma cells |
| Q36460975 | Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed? |
| Q38969791 | The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. |
| Q58760425 | Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications |
| Q33723810 | Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma |
Search more.